263 related articles for article (PubMed ID: 23832706)
21. Comparison of statistical signal detection methods within and across spontaneous reporting databases.
Candore G; Juhlin K; Manlik K; Thakrar B; Quarcoo N; Seabroke S; Wisniewski A; Slattery J
Drug Saf; 2015 Jun; 38(6):577-87. PubMed ID: 25899605
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological prioritisation of signals of disproportionate reporting: proposal of an algorithm and pilot evaluation.
Salvo F; Raschi E; Moretti U; Chiarolanza A; Fourrier-Réglat A; Moore N; Sturkemboom M; De Ponti F; Poluzzi E; Pariente A
Eur J Clin Pharmacol; 2014 May; 70(5):617-25. PubMed ID: 24595599
[TBL] [Abstract][Full Text] [Related]
23. Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase.
Sandberg L; Taavola H; Aoki Y; Chandler R; Norén GN
Drug Saf; 2020 Oct; 43(10):999-1009. PubMed ID: 32564242
[TBL] [Abstract][Full Text] [Related]
24. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
[TBL] [Abstract][Full Text] [Related]
25. A potential event-competition bias in safety signal detection: results from a spontaneous reporting research database in France.
Salvo F; Leborgne F; Thiessard F; Moore N; Bégaud B; Pariente A
Drug Saf; 2013 Jul; 36(7):565-72. PubMed ID: 23673817
[TBL] [Abstract][Full Text] [Related]
26. Spontaneous reporting of adverse drug reactions by nurses.
Bäckström M; Mjörndal T; Dahlqvist R
Pharmacoepidemiol Drug Saf; 2002 Dec; 11(8):647-50. PubMed ID: 12512239
[TBL] [Abstract][Full Text] [Related]
27. Reporting of fatal adverse drug reactions.
Liu BA; Knowles SR; Mittmann N; Einarson T; Shear NH
Can J Clin Pharmacol; 2001; 8(2):84-8. PubMed ID: 11493936
[TBL] [Abstract][Full Text] [Related]
28. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
[TBL] [Abstract][Full Text] [Related]
29. Data-Driven Identification of Adverse Event Reporting Patterns for Japan in VigiBase, the WHO Global Database of Individual Case Safety Reports.
Wakao R; Taavola H; Sandberg L; Iwasa E; Soejima S; Chandler R; Norén GN
Drug Saf; 2019 Dec; 42(12):1487-1498. PubMed ID: 31559542
[TBL] [Abstract][Full Text] [Related]
30. A 6-year retrospective study of adverse drug reactions due to drug-drug interactions between nervous system drugs.
Shi QP; He XD; Yu ML; Zhu JX; Liu Y; Ding F; Sang R; Jiang XD; Zhang SQ
Int J Clin Pharmacol Ther; 2014 May; 52(5):392-401. PubMed ID: 24691061
[TBL] [Abstract][Full Text] [Related]
31. Impact of stratification on adverse drug reaction surveillance.
Hopstadius J; Norén GN; Bate A; Edwards IR
Drug Saf; 2008; 31(11):1035-48. PubMed ID: 18840023
[TBL] [Abstract][Full Text] [Related]
32. Nurses are increasingly involved in pharmacovigilance in Sweden.
Ulfvarson J; Mejyr S; Bergman U
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):532-7. PubMed ID: 17072915
[TBL] [Abstract][Full Text] [Related]
33. Detection of cluster adverse drug events in the spontaneous reporting system of China using a disproportionality filter algorithm.
Wang M; Ye X; Ruan Y; Xu J; Guo X; Dong D; Feng H; He J
J Clin Pharm Ther; 2019 Dec; 44(6):952-957. PubMed ID: 31407823
[TBL] [Abstract][Full Text] [Related]
34. Building a structured monitoring and evaluating system of postmarketing drug use in Shanghai.
Du W; Levine M; Wang L; Zhang Y; Yi C; Wang H; Wang X; Xie H; Xu J; Jin H; Wang T; Huang G; Wu Y
Can J Clin Pharmacol; 2007; 14(1):e40-4. PubMed ID: 17237524
[TBL] [Abstract][Full Text] [Related]
35. Database size and power to detect safety signals in pharmacovigilance.
Hammond IW; Gibbs TG; Seifert HA; Rich DS
Expert Opin Drug Saf; 2007 Nov; 6(6):713-21. PubMed ID: 17967160
[TBL] [Abstract][Full Text] [Related]
36. Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area.
Grundmark B; Holmberg L; Garmo H; Zethelius B
Eur J Clin Pharmacol; 2014 May; 70(5):627-35. PubMed ID: 24599513
[TBL] [Abstract][Full Text] [Related]
37. Illusions of objectivity and a recommendation for reporting data mining results.
Hauben M; Reich L; Gerrits CM; Younus M
Eur J Clin Pharmacol; 2007 May; 63(5):517-21. PubMed ID: 17364192
[TBL] [Abstract][Full Text] [Related]
38. Adverse drug reaction reports for cardiometabolic drugs from sub-Saharan Africa: a study in VigiBase.
Berhe DF; Juhlin K; Star K; Beyene KG; Dheda M; Haaijer-Ruskamp FM; Taxis K; Mol PG
Trop Med Int Health; 2015 Jun; 20(6):797-806. PubMed ID: 25704305
[TBL] [Abstract][Full Text] [Related]
39. Reports of hyperkalemia after publication of RALES--a pharmacovigilance study.
Hauben M; Reich L; Gerrits CM
Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):775-83. PubMed ID: 16804951
[TBL] [Abstract][Full Text] [Related]
40. Possible occurrence of paraesthesia in patients taking norethisterone: an analysis on the WHO Global Individual Case Reports database (VigiBase).
Buccellato E; Biagi C; Vaccheri A; Melis M; Montanaro N; Motola D
Expert Opin Drug Saf; 2013 Sep; 12(5):615-9. PubMed ID: 23701188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
